Friday, May 29, 2026

FDA Approves Rhapsido (remibrutinib) for the Treatment of Chronic Spontaneous Urticaria

›
Novartis announced today that Rhapsido (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult...
Wednesday, May 27, 2026

FDA Approves Foundayo (orforglipron), the Only GLP-1 Pill for Weight Loss That Can be Taken Any Time of Day Without Food or Water Restrictions

›
Eli Lilly and Company (NYSE: LLY)  announced the FDA approval of   Foundayo™ (orforglipron) for adults with obesity, or overweight with weig...
Monday, May 25, 2026

Vitamin C may reduce cancer-linked digestive chemical reactions

›
In continuation of my update on Vitamin C A new study from the University of Waterloo uses mathematical modeling to examine how Vitamin C af...
Thursday, May 21, 2026

FDA Approves Lasix ONYU (furosemide) for Treatment of Edema in Heart Failure

›
SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix ONYU (fu...
Wednesday, May 20, 2026

FDA Approves Jascayd (nerandomilast) to Treat Idiopathic Pulmonary Fibrosis

›
Boehringer Ingelheim’s Jascayd (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) as an oral treatment...
Tuesday, May 19, 2026

Mavacamten improves obstruction in adolescents with hypertrophic cardiomyopathy

›
In continuation of my update on Mavacamten Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mava...
Monday, May 18, 2026

Investigational drug delivers mixed results for uncontrolled blood pressure

›
The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that...
Friday, May 15, 2026

Probing a paradoxical drug response for irregular heartbeat

›
                                                                               Mexiletine https://go.drugbank.com/drugs/DB00379 https://en.w...
Thursday, May 14, 2026

FDA Approves Ferabright (ferumoxytol injection) Contrast Agent for Magnetic Resonance Imaging of the Brain

›
Azurity Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA)  approval of  Ferabright (ferumoxytol injection), the fi...
Monday, May 11, 2026

Small molecule could slow or stop progress of Parkinson's disease and related brain disorders, not just treat symptoms

›
A team of researchers from NYU Abu Dhabi and the University of Denver has identified a promising small molecule that could help slow or halt...
Friday, May 8, 2026

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

›
Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for ...
Thursday, May 7, 2026

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

›
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra)  announced   the U.S. Food and Drug Administration (FDA)   acceptance the  review of the...
Thursday, April 30, 2026

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

›
Federal regulators on Wednesday approved Eli Lilly's new weight-loss pill, a second daily oral medication to treat obesity and other wei...
Wednesday, April 29, 2026

Study Details | NCT07506044 | Dexmedetomidine as an Adjuvant During Dural Puncture Epidural

›
In continuation of my update on Dexmedetomidine Study Overview Brief Summary: The study aimed to determine the effects of using varied doses...
Tuesday, April 28, 2026

Study Details | NCT07506395 | Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

›
In continuation of my update on  Psilocybin This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-forma...